2018
DOI: 10.3389/fphar.2018.00930
|View full text |Cite
|
Sign up to set email alerts
|

Controlled Drug Delivery by Polylactide Stereocomplex Micelle for Cervical Cancer Chemotherapy

Abstract: A stable doxorubicin (DOX)-loaded stereocomplex micelle drug delivery system was developed via the stereocomplex interaction between enantiomeric 4-armed poly(ethylene glycol)–poly(D-lactide) and poly(ethylene glycol)–poly(L-lactide) to realize control drug release and improve tumor cell uptake for efficient cervical carcinoma therapy. All these DOX-loaded micelles including poly(D-lactide)-based micelle (PDM/DOX), poly(L-lactide)-based micelle (PLM/DOX), and stereocomplex micelle (SCM/DOX) exhibited appropria… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
10
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 13 publications
(10 citation statements)
references
References 49 publications
0
10
0
Order By: Relevance
“…As a result, tumor cell activity was decreased with the drug delivery system compared to non-loaded drug performance. Increased tumor inhibition rates were also exhibited by doxorubicin-loaded stereocomplex micelles [41] .…”
Section: Applicationsmentioning
confidence: 96%
See 2 more Smart Citations
“…As a result, tumor cell activity was decreased with the drug delivery system compared to non-loaded drug performance. Increased tumor inhibition rates were also exhibited by doxorubicin-loaded stereocomplex micelles [41] .…”
Section: Applicationsmentioning
confidence: 96%
“…
Fig. 4 Schematic of design of doxorubicin-loaded stereocomplex micelle and administration to mouse subject [41] .
Fig.
…”
Section: Applicationsmentioning
confidence: 99%
See 1 more Smart Citation
“…Antitumor therapeutic effects of Pha@FPPC-mediated PDT at a light dosage of 90 J/cm 2 and drug dosage of 2 mg/kg were investigated by measuring tumor volume and survival period of C57/6J mice bearing B16-F10 melanoma in five groups (control, Pha@FPPC, Pha@PPC, FPPC, and Pha) (Figure 5B). Compared with the control group, on day 3 after PDT, Pha@FPPC, and Pha@PPC groups initiated significant difference ( P <0.01 and P <0.05, respectively), while other groups indicated significant difference on day 4–6 in variety, demonstrating encapsulation of Pha into drug-delivery carrier FPPC could significantly enhance the PDT antitumor effect of Pha in vivo due to EPR effect of tumor as micelle nanoparticles 2123. On day 7 after PDT, the destiny Pha@FPPC group showed a significant difference compared with every other group, indicating the advantage of folate-targeting strategy in retarding tumor proliferation due to its FA-mediated tumor targeting 1719.…”
Section: Resultsmentioning
confidence: 82%
“…As a result, on the one hand, it should be expected that Pha@FPPC could improve water-solubility and tumor cellular uptake of Pha and chidamide, and directionally release Pha in tumor sites by acid-triggering in a tumor’s slightly acidic environment, resulting in enhancing PDT antitumor efficacy of free Pha due to both its folate-mediated tumor-targeting and selectively accumulation at tumor site by EPR (enhanced permeability and retention) effect as micelle nanoparticles 2123. On the other hand, chidamide segment in Pha@FPPC could not only exert its own antitumor effect as an HDACi, but also augment PDT antitumor efficiency of Pha probably due to prevention the potential relapse and metastasis via inhibiting the elevated activity of HDAC induced by PDT.…”
Section: Introductionmentioning
confidence: 99%